Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
miglustat (zavesca) (1 trial)
acetylcysteine (mucomyst) (1 trial)
Gangliosidoses (Phase 4)
Gangliosidoses, GM2 (Phase 4)
Gangliosidosis, GM1 (Phase 4)
Gaucher Disease (Phase 2)
Inflammation (Phase 2)
Sandhoff Disease (Phase 4)
Tay-Sachs Disease (Phase 4)
Trials (2 total)
Trial APIs (2 total)